NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cibus, Inc. (CBUS) Stock Analysis

Cibus, Inc. (CBUS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CBUS

$1.41

+$0.02 (+1.44%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CBUS with… →

CBUS Key Statistics

As of Oct 21, 2026
Trading
Open
$1.40
Previous Close
$1.39
Day's Range
1.39–1.43
52-Week Range
1.09–4.19
Volume
44.99K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.57
Valuation
Market Cap
$107.00M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
24.61
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.62
Financials (FY)
Revenue (FY)
$3.64M−14.62%
Net Income (FY)
−$127.09M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.43M
1-Year Return
−9.03%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
146.39K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CBUS closed at $1.41, −9.03% over 1 year.

Cibus, Inc. (CBUS) has a market capitalization of $107.00M.

In fiscal 2025, CBUS reported revenue of $3.64M.

CBUS Stock Return by Calendar Year

Cibus, Inc. (CBUS) return since Jul 2017: what $10,000 became

1 year
$10,000 $9,097
−9.03%
5 years
$10,000 $99
−99.01%
Since Jul 2017
$10,000 $25
−99.75%

If you had invested $10,000 in Cibus, Inc. (CBUS) at the close on July 20, 2017, the earliest close on record here, it would have been worth $25 at the close on October 21, 2026: −99.75% in total, −47.65% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−18.97%
2025−37.41%
2024−85.85%
2023+165.41%
2022−93.05%
2021−49.53%
2020−39.80%
2019−32.34%
2018−52.97%
2017 (partial year)+95.82%

As of October 21, 2026.

CBUS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.64M−$127.09M−3,492.3%
2024$4.26M−$251.39M−5,898.4%
2023$1.82M−$267.63M−14,729.1%
2022$157.00K−$16.89M−10,758.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.64M$3.64M−$67.46M−$127.09M−3,492.3%
2024$4.26M$4.26M−$76.96M−$251.39M−5,898.4%
2023$1.82M$1.82M−$69.46M−$267.63M−14,729.1%
2022$157.00K$157.00K−$22.37M−$16.89M−10,758.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CBUS Valuation vs Biotechnology Median

Median of 608 stocks
MetricCBUSBiotechnology medianvs median
P/S ratio24.6113.3085% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cibus, Inc. (CBUS) carries a market capitalisation of $107.00M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 118.

Over the past 52 weeks the price has ranged from $1.09 to $4.19. CBUS last closed at $1.41 on October 21, 2026. That is +$0.02 (+1.44%) against the previous close. The latest close sits 29.36% above that 52-week low.

Financial Health

In fiscal 2025, Cibus, Inc. reported revenue of $3.64M. Against the prior fiscal year total of $4.26M, that is a change of −14.62%. The same year closed with a net loss of $127.09M. Trailing earnings per share are −1.62.

Across the 4 fiscal years on file, revenue moves from $157.00K in 2022 to $3.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 24.61 times revenue. On price-to-sales that is 85.09% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.57. Daily returns over the trailing 9 years annualize to a volatility of 103.78%. The trailing one-year total return is −9.03%. Across 5 years the annualized return works out at −60.27%.

Growth & Income

The record shows no dividend for CBUS.

So far in 2026 the total return is −18.97%. Across the complete calendar years on file, 2023 returned +165.41% and 2022 returned −93.05%. Of the 8 complete calendar years on file, 1 finished higher.

Peer Comparison

Cibus, Inc. (CBUS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cibus, Inc. CBUS $107.00M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cibus, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cibus, Inc.

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Visit website →